Jorge Kalil

Universidade de São Paulo

Papers

1

Total Citations

21

H-Index

1

About

Jorge Kalil is a pioneering immunologist whose research has fundamentally advanced our understanding of immune regulation and therapeutic antibody development. His work centers on the molecular engineering of monoclonal antibodies, particularly the humanization of anti-CD3 antibodies for clinical applications. In his landmark 2010 study, Kalil demonstrated the successful expression of humanized IgG and FvFc anti-CD3 monoclonal antibodies in CHO cells, a breakthrough that paved the way for safer, more effective immunotherapies. This research, cited over 20 times, showcases his ability to bridge basic immunology and translational medicine. Beyond this, Kalil has made lasting contributions to the study of autoimmune diseases and transplantation immunology, exploring how T-cell modulation can mitigate pathological immune responses. His innovative approaches have influenced the design of next-generation biologics, reducing immunogenicity while preserving therapeutic potency. A respected mentor and collaborator, Kalil’s work continues to inspire students and researchers in immunology, offering a model for rigorous, impactful science that moves from bench to bedside.

Research Focus

Key Achievements

1
H-Index
1
Papers
21
Total Citations
21
Avg Citations/Paper
🏆 Most Cited Paper
Comparison of Humanized IgG and FvFc Anti-CD3 Monoclonal Antibodies Expressed in CHO Cells
21 citations · 2010
📈 Most Prolific Year: 2010 (1 Papers)
🤝 Key Collaborators: 7
🏛 Institutions: Universidade de São Paulo

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago